首页|Effectiveness of infliximab after adalimumab failure in Crohn's disease

Effectiveness of infliximab after adalimumab failure in Crohn's disease

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure.METHODS:A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure.Patients were identified using a large Spanish database (ENEIDA).RESULTS:We included 15 Crohn's disease patients who received infliximab after adalimumab failure.Five patients discontinued adalimumab due to loss of response,3 due to adverse events and 7 due to partial response.After infliximab therapy was started,all patients who had interrupted adalimumab due to loss of efficacy regained response.All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab,but 2 developed adverse events.None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab.CONCLUSION:Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response,however,the benefit of infliximab in primary nonresponders was not established.

AdalimumabBiologicsCrohn's diseaseInfliximabSwitch

María Chaparro、Montserrat Andreu、Manuel Barreiro-de Acosta、Esther García-Planella、Elena Ricart、Eugeni Domènech、María Esteve、Olga Merino、Pilar Nos、Mireia Pe(n)alva、Javier P Gisbert

展开 >

Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Princesa(IP)and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas(CIBEREHD),28006 Madrid, Spain

Americio 17, portal E 2°C, 28021 Madrid

Department of Gastroenterology, Hospital del Mar, 08003 Barcelona, Spain

Department of Gastroenterology,Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain

Department of Gastroenterology, Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain

Department of Gastroenterology, Hospital Clínic,Barcelona, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 08916 Badalona, Spain

Department of Gastroenterology, Hospital Germans Trias i Pujol and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas(CIBEREHD),08916 Badalona, Spain

Department of Gastroenterology, Hospital Mutua de Terrassa, 08221 Barcelona, Spain

Department of Gastroenterology, Hospital de Cruces, 48903 Bilbao, Spain

Department of Gastroenterology, Hospital Universitario La Fe and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas(CIBEREHD), 46009 Valencia, Spain

Department of Gastroenterology, Hospital de Bellvitge, 08907 Barcelona, Spain

展开 >

2012

10.3748/wjg.v18.i37.5219

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(37)
  • 27